Video

Cristi Radford on the Nurse Navigator's Role in Genetic Counseling

Cristi Radford, a Certified Genetic Counselor, explains the multifaceted role that oncology nurse navigators play in the genetic counseling process.

Cristi Radford, MS, CGC, Certified Genetic Counselor, Genetic Education Program, Sarasota Memorial Hospital, explains the multifaceted role that oncology nurse navigators play in the genetic counseling and cancer risk assessment process.

Radford believes that nurse navigators are able to impact genetic counseling the most in the community setting, since this is where many patients are diagnosed and treated. As one of the first individuals to interact with a patient, the nurse navigator should look for signs of a hereditary symptom in order to determine if the patient is a good candidate for genetic counseling or risk assessment. If the navigator feels the patient's cancer is hereditary they can advise the treatment team and the patient to seek genetic counseling.

Nurse navigators may also be tasked with addressing many of the myths associated with genetic counseling and cancer risk assessment. Patients have many questions regarding their insurance and possible discrimination that nurse navigators may need to answer first in order to move forward with the risk assessment process.

<<<

View more from the 2012 NCONN Conference

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie